Blue Owl Capital Inc. Class A Common Stock vs Koninklijke Philips NV — how do they compare? Blue Owl Capital Inc. Class A Common Stock trades at $8.81 (market cap $6.35B), while Koninklijke Philips NV trades at $25.28 (market cap $24.24B). The key difference: Koninklijke Philips NV is far larger — about 3.8× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays the higher dividend (9.8%). Which is the better fit depends on your goals — on Pluang, investors hold Blue Owl Capital Inc. Class A Common Stock for 0 Days and Koninklijke Philips NV for 84 Days on average.
| OWL | PHG | |
|---|---|---|
Market Cap | $6.35B | $24.24B |
Volume | 15,716,423 | 982,766 |
Sector | Financials | Health |
52-Week High | $17.17 | $32.91 |
52-Week Low | $8.23 | $23.81 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $10.53B | $30.57B |
Dividend Yield | 9.8% | 4.07% |
Signals from Pluang's Aura AI — not financial advice
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
PHG trades at $25.00, up 1.05% today, with a bullish technical signal despite mixed oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.57 exceeding the $0.40 estimate. Revenue for 2025 was $17.83 billion, with a net income margin of 5.01%, showing a recovery from prior losses. Recent news highlights product launches and strategic partnerships in healthcare technology.
The outlook is cautiously optimistic, supported by earnings momentum and innovation, but risks include competitive pressures and debt levels. Analysts are mixed, with a 'Hold' consensus, while institutional buying activity indicates underlying confidence. Valuation metrics like a P/E of 19.49 suggest the stock is fairly priced relative to peers.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →